Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage Occlusion

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 234 participants.

Also called NCT07840365

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 234 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07840365
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07840365. Randomized; no masking; primary purpose prevention. Start 2026-09-01 (actual); primary completion 2028-12-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage Occlusion
Acronym
INTEGRAL
Condition
Atrial Fibrillation (AF)
Intervention (Drug)
Half-Dose of novel OAC
Intervention (Drug)
Low-dose ASA
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation (class: other)

Record details

Record id
cardio:ct-nct07840365
Content hash
460c1402935fb22d94b6a59dd937848de29db1df32f72faf49ae30c3b57b88d5